SUN BIOPHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01. Regulation FD Disclosure.

On January 24, 2020, Sun BioPharma, Inc. issued a press release regarding the results from its Phase 1 clinical trial. The full text of the press release is set forth in Exhibit 99.1 attached hereto and is incorporated by reference in this current report on Form 8-K as if fully set forth herein.

This information, including Exhibit 99.1, shall not be deemed to be "filed" with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)   Exhibits



Exhibit No.                  Description                      Method of Filing
   99.1         Press release dated January 24, 2020.     Furnished Electronically

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses